HAVCR2 and autoimmune disease: In autoimmune diseases, IFN-β therapy increased the expression of TIM-3 and thus enhanced protective immunity, whereas in chronic viral infections and cancers, TIM-3 expression repressed immunosurveillance and inhibited the immune clearance (Anderson et al. 2016; Wolf et al. 2020).